The Latest Cardiac and Vascular News
Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson PARIS–(BUSINESS WIRE)–Sofinnova Partners, a leading European life sciences venture […]
– Early preclinical studies show peptide D6PV has the ability to activate the enzyme called Lipo-Protein Lipase (LPL), rapidly (within 1 -3 hours) reducing the number of triglycerides in the bloodstream – D6PV, an investigational drug, is being developed to […]
WALTHAM, Mass., May 21, 2019 /PRNewswire/ — Corvidia Therapeutics Inc., a clinical stage biotechnology company, today announced the appointment of Dr. Preston Klassen, M.D., M.H.S. to its Board of Directors. Dr. Klassen is presently Executive Vice President, Head of Research and Development at Arena […]
WALTHAM, Mass.–(BUSINESS WIRE)– Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the appointment of Marc de Garidel as Chief Executive Officer. Mr. de Garidel succeeds Corvidia’s Michael Davidson, M.D., who will remain on the company’s executive team as […]
